Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$27.0 million.

  • Zentalis Pharmaceuticals' Free Cash Flow rose 3878.31% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$134.0 million, marking a year-over-year increase of 2215.61%. This contributed to the annual value of -$171.1 million for FY2024, which is 1790.94% up from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Free Cash Flow stood at -$27.0 million for Q3 2025, which was up 3878.31% from -$34.7 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Free Cash Flow's 5-year high stood at -$27.0 million during Q3 2025, with a 5-year trough of -$79.6 million in Q2 2023.
  • For the 4-year period, Zentalis Pharmaceuticals' Free Cash Flow averaged around -$42.7 million, with its median value being -$39.7 million (2024).
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Free Cash Flow crashed by 8379.86% in 2023, and later soared by 5562.48% in 2024.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Free Cash Flow stood at -$37.5 million in 2022, then decreased by 8.76% to -$40.8 million in 2023, then increased by 2.62% to -$39.7 million in 2024, then soared by 32.09% to -$27.0 million in 2025.
  • Its Free Cash Flow was -$27.0 million in Q3 2025, compared to -$34.7 million in Q2 2025 and -$32.6 million in Q1 2025.